Sectoral Asset Management
Sectoral Asset Management, Inc. is an employee-owned investment manager that specializes in managing global investment portfolios within the healthcare sector. Founded in 2000 and headquartered in Montreal, Quebec, with additional offices in Geneva, Switzerland, the firm manages approximately US $4.0 billion in assets. It provides services to various clients, including investment companies, pooled investment vehicles, banking institutions, and high net worth individuals. Sectoral focuses on late-stage healthcare investments in private equity, while also managing separate equity portfolios, mutual funds, and hedge funds. Its investment strategy includes a long-short approach and emphasizes small-cap companies, utilizing fundamental and scenario analysis for stock selection. The firm's investment activities are supported by a combination of in-house and external research, primarily targeting the biotechnology and healthcare sectors. Sectoral benchmarks its performance against several indices, including those related to pharmaceuticals and overall market returns.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.